Proactive Investors - Run By Investors For Investors

Appili Therapeutics starts trading on the TSX Venture Exchange

The company is focused on the acquisition and development of novel treatments targeting unmet needs in infectious disease
Toronto
Shares of Appili began trading at C$1.10 on Tuesday morning

Appili Therapeutics Inc (CVE:APLI), a biopharmaceutical company, saw its shares spring to life on the TSX Venture Exchange Tuesday.

The Halifax, Nova Scotia-based company is focused on the acquisition and development of novel treatments targeting unmet needs in infectious disease.

Shares of Appili began trading at C$1.10 on Tuesday morning before resting at C$1 by mid-afternoon.

READ: Antibe Therapeutics updates on Phase 2 progress of lead drug ATB-346

Appili currently has 33.5 million shares outstanding, giving it a valuation of around C$33.5 million at the current share price levels.

The company, incorporated in 2015, has a unique business model in the biopharmaceutical sector. Instead of focusing on a select few drugs, Appili builds and advances a diverse portfolio of anti-infective programs before pairing with strategic partners to continue towards commercialization.

“Appili has a clear and unwavering mission: to tackle the growing number of threats in the infectious disease landscape,” said Kevin Sullivan, Appili’s CEO. “Listing our shares on the TSXV is an important milestone in our maturation in support of this mission.”

Sullivan said that the company has made “strong efforts” to be efficient with shareholder capital, combining C$15.4 million in equity raised with over C$19 million in non-dilutive funding to advance its programs.

“Our public listing marks an important inflection point in our ability to deepen our reach into this market and demonstrate that it is possible to invest in a compelling and attractive social mission and business opportunity in parallel,” Sullivan said.

In the current pipeline are three assets geared towards fighting infectious diseases such as a vaccine for tularemia being developed to mitigate the threat against biological weapons.

Contact Angela at [email protected]

Follow her on Twitter @AHarmantas

View full APLI profile View Profile

Appili Therapeutics Inc Timeline

Related Articles

skin
April 17 2019
Driving growth was Lojuxta, used to treat a rare and life-threatening disorder that causes abnormally high levels of bad cholesterol. Its sales grew to €13.6mln, up 14.2% year-on-year
scientist at petrie dish
May 15 2019
Here we take a closer look at Midatech Pharma PLC (LON:MTPH)
patch
May 19 2019
The New Jersey company's lead product is Twirla, a low-dose prescription contraceptive applied once weekly for three weeks, followed by a week without the patch
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use